BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

935 related articles for article (PubMed ID: 19699029)

  • 1. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
    Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
    Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
    Beyer M; Kiweler N; Mahboobi S; Krämer OH
    Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
    Zhou C; Qiu L; Sun Y; Healey S; Wanebo H; Kouttab N; Di W; Yan B; Wan Y
    Int J Oncol; 2006 Jul; 29(1):269-78. PubMed ID: 16773209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
    Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
    Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of the tumor suppressor C-terminal Src kinase (Csk)-binding protein (Cbp)/PAG1 is mediated by epigenetic histone modifications via the mitogen-activated protein kinase (MAPK)/phosphatidylinositol 3-kinase (PI3K) pathway.
    Suzuki K; Oneyama C; Kimura H; Tajima S; Okada M
    J Biol Chem; 2011 May; 286(18):15698-706. PubMed ID: 21388951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative effects of TSA, PXD‑101 and MS‑275 in A2780 and MCF7 cells: Acetylated histone H4 and acetylated tubulin as markers for HDACi potency and selectivity.
    Androutsopoulos VP; Spandidos DA
    Oncol Rep; 2017 Dec; 38(6):3412-3418. PubMed ID: 29039546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-455-3p modulates cartilage development and degeneration through modification of histone H3 acetylation.
    Chen W; Chen L; Zhang Z; Meng F; Huang G; Sheng P; Zhang Z; Liao W
    Biochim Biophys Acta; 2016 Dec; 1863(12):2881-2891. PubMed ID: 27638301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of buffalo (Bubalus bubalis) donor cells with trichostatin A and 5-aza-2'-deoxycytidine alters their growth characteristics, gene expression and epigenetic status and improves the in vitro developmental competence, quality and epigenetic status of cloned embryos.
    Saini M; Selokar NL; Agrawal H; Singla SK; Chauhan MS; Manik RS; Palta P
    Reprod Fertil Dev; 2016 Apr; 28(6):824-37. PubMed ID: 25409339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells.
    An X; Wei Z; Ran B; Tian H; Gu H; Liu Y; Cui H; Zhu S
    Anticancer Agents Med Chem; 2020; 20(17):2114-2124. PubMed ID: 32593284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate.
    Sekhavat A; Sun JM; Davie JR
    Biochem Cell Biol; 2007 Dec; 85(6):751-8. PubMed ID: 18059533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic regulation of myofibroblast differentiation and extracellular matrix production in nasal polyp-derived fibroblasts.
    Cho JS; Moon YM; Park IH; Um JY; Moon JH; Park SJ; Lee SH; Kang HJ; Lee HM
    Clin Exp Allergy; 2012 Jun; 42(6):872-82. PubMed ID: 22239687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trichostatin A induces 5-lipoxygenase promoter activity and mRNA expression via inhibition of histone deacetylase 2 and 3.
    Pufahl L; Katryniok C; Schnur N; Sorg BL; Metzner J; Grez M; Steinhilber D
    J Cell Mol Med; 2012 Jul; 16(7):1461-73. PubMed ID: 21883892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation.
    Mahal K; Kahlen P; Biersack B; Schobert R
    Exp Cell Res; 2015 Aug; 336(2):263-75. PubMed ID: 26101158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
    Cai J; Wei H; Hong KH; Wu X; Zong X; Cao M; Wang P; Li L; Sun C; Chen B; Zhou G; Chen J; Ji M
    Bioorg Med Chem; 2015 Jul; 23(13):3457-71. PubMed ID: 25953722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of intestinal serotonin transporter expression via epigenetic mechanisms: role of HDAC2.
    Gill RK; Kumar A; Malhotra P; Maher D; Singh V; Dudeja PK; Alrefai W; Saksena S
    Am J Physiol Cell Physiol; 2013 Feb; 304(4):C334-41. PubMed ID: 23195070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury.
    Marumo T; Hishikawa K; Yoshikawa M; Hirahashi J; Kawachi S; Fujita T
    Am J Physiol Renal Physiol; 2010 Jan; 298(1):F133-41. PubMed ID: 19906951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
    Duan H; Heckman CA; Boxer LM
    Mol Cell Biol; 2005 Mar; 25(5):1608-19. PubMed ID: 15713621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
    Lee SH; Kim J; Kim WH; Lee YM
    Oncogene; 2009 Jan; 28(2):184-94. PubMed ID: 18850007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.